SUGAR LAND--December 11, 2012--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Over the past few years, plant closures throughout the pharmaceutical-biotech industry had become so common that news of another barely spurred interest beyond those immediately affected. Across North America, the dreaded announcements rolled out as the industry began running a meaner and leaner operational plan. Despite the regularity of these closings, some perceived that a few of the sites, the mega sites, were somehow sacrosanct. Despite evidence to the contrary, Pfizer's (NYSE:PFE) (New York, New York) 2010 decision to severely trim operations at its 550-acre, 2.5 million-square-foot campus in Pearl River, New York, was met with almost a state of disbelief for locals.